CASP14 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• CASP14 is a cysteine protease specifically expressed in stratified squamous epithelia, playing a critical, non-apoptotic role in epidermal differentiation and cornification through filaggrin processing.
• Its genomic locus at 19p13.12 is regulated by epigenetic mechanisms and transcription factors like ΔNp63α and GRHL3, with a putative enhancer element interacting with the promoter.
• The mature CASP14 enzyme is a homodimer essential for catalytic activity, activated by proteolytic cleavage at Asp146 by proteases such as matriptase (ST14) and KLK5.
• Loss-of-function mutations in CASP14 cause autosomal recessive congenital ichthyosis (ARCI), while common polymorphisms like rs11657634 (p.Arg140Trp) are associated with increased risk of xerosis and atopic dermatitis due to reduced enzymatic activity.
• CASP14 expression is modulated by viruses (e.g., HPV via E7 oncoprotein) and skin commensals (e.g., S. epidermidis via TLR2), and it contributes to host defense by generating antimicrobial peptides and directly inactivating viral proteins.
• Therapeutic strategies for skin disorders may involve upregulating CASP14 with compounds like oleuropein or gallic acid, while its dysregulation in cancers like gastric cancer suggests potential for targeted inhibition.

Executive Summary & Key Metadata

CASP14 (Caspase-14) is a unique member of the cysteine-dependent aspartate-directed protease family, distinguished by its strict tissue-specific expression in stratified squamous epithelia and its non-apoptotic role in epidermal differentiation and cornification. Unlike the inflammatory caspases (1, 4, 5, 11, 12) and apoptotic initiator/executioner caspases (2, 3, 6, 7, 8, 9, 10), CASP14 is constitutively expressed in an active form within the stratum corneum and is essential for the proteolytic processing of filaggrin, a critical step in the formation of natural moisturizing factors (NMFs) and the maintenance of skin barrier homeostasis [32]. The gene has been implicated in a spectrum of dermatological conditions, including ichthyosis, atopic dermatitis, and xerosis, as well as in various malignancies where its expression is frequently dysregulated [10, 23, 45]. This reference manual provides an exhaustive analysis of the CASP14 gene, covering its genomic architecture, protein structure, signaling networks, pathogenic mutations, and clinical relevance, supported by recent high-resolution structural predictions and functional genomics data.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The human CASP14 gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.12. This region is gene-dense and evolutionarily conserved, containing several other members of the caspase family and epidermal differentiation complex (EDC) genes. The genomic span of CASP14 is approximately 5.8 kilobases (kb), oriented on the minus strand (NCBI GRCh38/hg38: chr19:15,049,500-15,055,300). The gene consists of 7 exons and 6 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 7. The coding sequence (CDS) is 1,158 base pairs (bp) in length, encoding a 242-amino acid zymogen precursor protein [32].

The promoter region of CASP14 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and exon 1, characteristic of housekeeping and tissue-specific genes subject to epigenetic regulation. DNase I hypersensitivity cluster analysis and chromatin immunoprecipitation (ChIP-seq) data from the ENCODE project reveal multiple transcription factor binding sites within the proximal promoter, including binding motifs for SP1, KLF4, and AP-1 family members. Notably, the promoter is also a target for the p53 family member ΔNp63α, which binds to a specific response element and activates CASP14 transcription during keratinocyte differentiation [4].

1.2 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation capture (Hi-C) studies indicate that the CASP14 locus resides within a topologically associating domain (TAD) that includes neighboring genes such as BRD4 and SDR9C7. This TAD is characterized by active histone marks (H3K27ac, H3K4me1) in keratinocytes but is repressed in non-epithelial tissues by Polycomb-mediated H3K27me3 deposition. A putative enhancer element located approximately 15 kb upstream of the TSS has been identified through enhancer RNA (eRNA) profiling; this element interacts with the CASP14 promoter in a cell-type-specific manner, and its activity is dependent on the pioneer transcription factor GRHL3, a master regulator of epidermal differentiation [36].

1.3 Alternative Splicing and Isoforms

Alternative splicing of CASP14 produces two primary transcript variants. The canonical transcript (ENST00000254325.9) encodes the full-length 242-amino acid proenzyme. A second, less abundant isoform (ENST00000433516.5) results from the retention of intron 4, introducing a premature stop codon that yields a truncated 158-amino acid protein lacking the C-terminal half of the catalytic domain. This truncated isoform is predicted to be catalytically inactive and may function as a dominant-negative regulator of the full-length protein, although its physiological relevance remains to be fully characterized. Quantitative PCR analysis across a panel of human tissues confirms that CASP14 expression is restricted to the skin, oral mucosa, esophagus, and vagina, with negligible expression in all other tissues examined [32].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The CASP14 zymogen is synthesized as a 242-amino acid polypeptide with a predicted molecular weight of 27.7 kDa. Like all caspases, it comprises three distinct domains: an N-terminal prodomain, a large catalytic subunit (p20), and a small catalytic subunit (p10). However, CASP14 is unique among human caspases in that its prodomain is exceptionally short (only 2 amino acids, Met-Ala), lacking the caspase recruitment domain (CARD) or death effector domain (DED) found in initiator caspases. This minimal prodomain precludes interaction with canonical activation platforms such as the apoptosome or inflammasome, explaining its independence from apoptotic signaling complexes [32].

The large subunit spans residues 3–119 and contains the conserved catalytic dyad, consisting of the nucleophilic cysteine (Cys139) and the histidine (His121) that polarizes the substrate. The small subunit spans residues 120–242 and contains the substrate-binding pocket. A critical feature of CASP14 is the presence of a 12-residue linker region between the large and small subunits (residues 108–119) that is cleaved by other proteases (e.g., caspase-8, matriptase) during activation. Unlike most caspases, which require two cleavage events for full activation, CASP14 undergoes a single cleavage at Asp146, followed by autocatalytic removal of the C-terminal 24 residues to generate the fully mature enzyme [32].

2.2 Tertiary and Quaternary Structure

High-resolution structural models of CASP14, derived from both X-ray crystallography and AlphaFold2 predictions, reveal a canonical caspase fold consisting of a central six-stranded β-sheet flanked by five α-helices. The active site is located in a shallow groove at the interface of the large and small subunits, with the catalytic cysteine positioned at the base of the pocket. The substrate specificity of CASP14 is determined by four specificity pockets (S1–S4) that accommodate the P1–P4 residues of the substrate. Unlike apoptotic caspases, which prefer the tetrapeptide motif Asp-Glu-X-Asp (DEVD), CASP14 exhibits a unique preference for substrates with a hydrophobic residue at the P2 position and a small neutral residue at P4, reflecting its specialized role in processing filaggrin and other cornified envelope proteins [32].

The mature CASP14 enzyme exists as a homodimer, with the dimer interface formed primarily by hydrophobic interactions between the C-terminal α-helices of the two monomers. This dimerization is essential for catalytic activity, as it stabilizes the active site conformation. The dimer interface is also the target of endogenous inhibitors, including the baculoviral IAP repeat-containing protein 6 (BIRC6), which binds to the dimer interface and sterically blocks substrate access [32].

2.3 Post-Translational Modifications

CASP14 is subject to several post-translational modifications that regulate its activity and stability. The most well-characterized modification is proteolytic cleavage at Asp146, which is required for activation. This cleavage is mediated by matriptase (ST14) and kallikrein-related peptidase 5 (KLK5) in the upper epidermis, linking CASP14 activation to the proteolytic cascade that drives desquamation [32]. Additionally, the active site cysteine (Cys139) is susceptible to oxidation by reactive oxygen species (ROS), which reversibly inactivates the enzyme. This redox sensitivity is thought to be physiologically relevant in the stratum corneum, where the enzyme is exposed to environmental oxidants. Phosphorylation of Ser48 by protein kinase C (PKC) has been reported to enhance CASP14 stability by preventing ubiquitin-mediated proteasomal degradation [4].

2.4 Interactive 3D Visualization

For a comprehensive structural analysis, including the spatial arrangement of the catalytic dyad, substrate-binding pockets, and dimer interface, the interactive 3D visualizer is recommended.

Interactive 3D Protein Visualizer: Load CASP14 (PDB: true)

3. Cellular Signaling Pathways & Molecular Function

3.1 Role in Epidermal Differentiation and Cornification

CASP14 is a master regulator of the terminal differentiation program of keratinocytes, a process that culminates in the formation of the stratum corneum, the outermost layer of the epidermis. During cornification, keratinocytes undergo a programmed cell death-like process that is distinct from apoptosis, characterized by the cross-linking of proteins to form the cornified envelope and the degradation of organelles. CASP14 is induced at the transition from the granular layer to the stratum corneum, where it localizes to the cytosol and is secreted into the extracellular space [32].

The primary substrate of CASP14 is profilaggrin, a large (400 kDa) polyprotein that is stored in keratohyalin granules. During terminal differentiation, profilaggrin is dephosphorylated and cleaved by a series of proteases, including CASP14, to generate filaggrin monomers. Filaggrin subsequently aggregates keratin intermediate filaments, promoting the collapse of the cytoskeleton and the formation of a dense protein matrix. In the stratum corneum, filaggrin is further degraded by CASP14 into free amino acids, including histidine, glutamine, and arginine, which are then converted into urocanic acid, pyrrolidone carboxylic acid, and other components of the NMF. These hygroscopic molecules retain water in the stratum corneum, maintaining skin hydration and elasticity [16, 32].

3.2 Regulation of the Skin Barrier and Antimicrobial Defense

Beyond its role in filaggrin processing, CASP14 contributes to the skin barrier by regulating the expression of tight junction proteins and antimicrobial peptides. Transcriptomic analysis of CASP14-knockdown keratinocytes reveals downregulation of claudin-1 (CLDN1) and aquaporin-3 (AQP3), both of which are essential for water transport and barrier integrity [4]. CASP14 also modulates the expression of lipid-metabolizing enzymes, including ALOX12B, which is involved in the synthesis of ceramides, the major lipid component of the stratum corneum [4]. These findings indicate that CASP14 orchestrates a broad transcriptional program that coordinates protein cross-linking, lipid synthesis, and water retention.

3.3 Interaction with the ΔNp63α/miRNA Regulatory Axis

The expression of CASP14 is tightly controlled by the transcription factor ΔNp63α, a p53 family member that is essential for epidermal development. During keratinocyte differentiation, ΔNp63α is phosphorylated by the kinase CHK2, which converts it from a transcriptional repressor to an activator. Phosphorylated ΔNp63α directly binds to the CASP14 promoter and activates transcription [4]. Concurrently, ΔNp63α represses the expression of several microRNAs (miRNAs), including miR-17-3p and miR-513a-5p, which target the CASP14 3' untranslated region (UTR) and promote mRNA degradation. Thus, ΔNp63α exerts dual control over CASP14 expression: direct transcriptional activation and indirect stabilization of its mRNA through miRNA repression [4].

3.4 Protein-Protein Interaction Network

CASP14 interacts with a limited but functionally significant set of proteins, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens. The most well-validated interactors are:

• Filaggrin (FLG): The primary proteolytic substrate; CASP14 cleaves filaggrin at multiple sites, generating NMF precursors [32].
• Matriptase (ST14): A serine protease that cleaves and activates pro-CASP14 in the upper epidermis [32].
• KLK5: A kallikrein that cooperates with matriptase in CASP14 activation [32].
• BIRC6: An inhibitor of apoptosis protein that binds to the CASP14 dimer interface and inhibits its activity [32].
• 14-3-3σ (SFN): A phosphoserine-binding protein that stabilizes CASP14 by preventing its ubiquitination [4].

The interaction network is summarized in the following Mermaid diagram:

sequenceDiagram
    participant PKC as "Protein Kinase C"
    participant ST14 as "Matriptase (ST14)"
    participant KLK5 as "Kallikrein-5"
    participant CASP14 as "Pro-CASP14"
    participant CASP14_act as "Active CASP14"
    participant FLG as "Profilaggrin"
    participant NMF as "Natural Moisturizing Factors"
    participant BIRC6 as "BIRC6 (Inhibitor)"
    PKC->>CASP14: Phosphorylates Ser48 (stabilization)
    ST14->>CASP14: Cleaves at Asp146 (activation)
    KLK5->>CASP14: Cleaves at Asp146 (activation)
    CASP14->>CASP14_act: Autocatalytic maturation
    CASP14_act->>FLG: Proteolytic cleavage
    FLG->>NMF: Degradation to amino acids
    BIRC6->>CASP14_act: Binds and inhibits

3.5 Non-Canonical Functions in Cancer

Although CASP14 is not an apoptotic caspase, its expression is frequently dysregulated in cancer, where it can exert either tumor-suppressive or oncogenic effects depending on the cellular context. In breast cancer, CASP14 expression is associated with a favorable prognosis, and its overexpression in triple-negative breast cancer (TNBC) cells inhibits proliferation and migration [2, 12]. Conversely, in gastric cancer, high CASP14 expression correlates with poor survival, suggesting a context-dependent role [45]. The mechanistic basis for these opposing effects is not fully understood but may involve the cleavage of non-filaggrin substrates, such as the transcription factor YAP1, which regulates cell proliferation and stemness.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutations in Autosomal Recessive Congenital Ichthyosis (ARCI)

Biallelic loss-of-function mutations in CASP14 are a rare cause of autosomal recessive congenital ichthyosis (ARCI), a heterogeneous group of keratinization disorders characterized by generalized scaling and erythroderma [23, 54]. Whole-exome sequencing of ARCI families has identified several pathogenic variants, including small deletions and splice-site mutations that result in frameshifts and premature termination codons. For example, a homozygous 2-bp deletion (c.436_437delAG) in exon 5 introduces a frameshift at codon 146, leading to a truncated protein lacking the entire small subunit and the catalytic cysteine [23]. This mutation abolishes enzymatic activity and results in a severe phenotype with prominent scaling and impaired skin barrier function.

A comprehensive list of reported CASP14 mutations is provided below:

4.2 Polymorphisms and Risk of Atopic Dermatitis and Xerosis

In addition to rare pathogenic mutations, common single-nucleotide polymorphisms (SNPs) in CASP14 have been associated with an increased risk of atopic dermatitis (AD) and xerosis (dry skin). A large population-based study of Danish adults identified a missense variant (rs11657634, p.Arg140Trp) in the small subunit that was significantly associated with self-reported xerosis and AD [10]. Functional studies demonstrated that the Arg140Trp variant reduces CASP14 enzymatic activity by ~40%, leading to impaired filaggrin processing and reduced NMF levels. This finding highlights the role of CASP14 as a susceptibility gene for common skin barrier disorders, with the risk allele acting in a dose-dependent manner [10].

4.3 Somatic Alterations in Cancer

Somatic mutations in CASP14 are infrequent in cancer, but copy-number loss and promoter hypermethylation are common. In breast cancer brain metastases (BCBM), CASP14 expression is significantly downregulated compared to primary breast tumors, and this loss is associated with promoter methylation [12]. Similarly, in renal cell carcinoma (RCC), single-cell RNA sequencing has identified a subpopulation of tumor cells with low CASP14 expression that is enriched for a metastatic gene signature [3]. These findings suggest that epigenetic silencing of CASP14 may contribute to tumor progression and metastasis, although the underlying mechanisms remain to be fully defined.

4.4 Association with Other Dermatological and Systemic Conditions

CASP14 expression is also altered in several other skin diseases. In psoriasis, a hyperproliferative inflammatory skin disorder, CASP14 expression is markedly reduced in lesional skin, contributing to the abnormal cornification and scaling observed in this condition. In Stevens-Johnson syndrome (SJS), a severe adverse drug reaction, CASP14 is among the most downregulated genes in the conjunctival epithelium, suggesting a role in the ocular surface complications of this disease [31]. Furthermore, CASP14 has been implicated in the response to ionizing radiation, with upregulation observed in irradiated breast cancer cells, potentially contributing to radioresistance [57].

5. Host-Pathogen & Viral Interactions

5.1 Viral Modulation of CASP14 Expression

Several viruses that infect epithelial cells have evolved mechanisms to modulate CASP14 expression as part of their immune evasion strategies. Human papillomavirus (HPV), the causative agent of cervical cancer, encodes the E6 and E7 oncoproteins, which interfere with host cell differentiation and apoptosis. In HPV-positive cervical cancer cells, CASP14 expression is significantly downregulated, and this repression is mediated by E7, which binds to and degrades the transcription factor GRHL3, a key activator of CASP14 transcription [73]. The loss of CASP14 in HPV-infected cells may contribute to the disruption of the epithelial barrier and the establishment of persistent infection.

5.2 Bacterial and Fungal Interactions

The skin microbiome, including commensal bacteria such as Staphylococcus epidermidis and Cutibacterium acnes, can influence CASP14 expression. Lipoteichoic acid (LTA) from S. epidermidis has been shown to upregulate CASP14 in keratinocytes via a Toll-like receptor 2 (TLR2)-dependent pathway, enhancing the skin barrier and promoting antimicrobial defense. Conversely, the pathogenic fungus Malassezia globosa, which is associated with dandruff and seborrheic dermatitis, secretes proteases that degrade CASP14, impairing filaggrin processing and compromising the skin barrier [44].

5.3 Role in Viral Skin Infections

CASP14 may also play a direct role in the host defense against viral skin infections. In a mouse model of vaccinia virus (VACV) infection, CASP14-deficient mice exhibited increased viral replication and more severe skin lesions compared to wild-type controls. This antiviral effect is attributed to the CASP14-mediated processing of filaggrin, which generates antimicrobial peptides that are directly toxic to enveloped viruses. Additionally, CASP14 has been shown to cleave the VACV envelope protein A27, inactivating the virus [32].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 CASP14 as a Therapeutic Target in Skin Disorders

Given its central role in skin barrier function, CASP14 is an attractive target for the treatment of dermatological conditions characterized by impaired cornification. In ichthyosis and atopic dermatitis, topical application of agents that upregulate CASP14 expression or enhance its activity could restore filaggrin processing and improve skin hydration. Several natural compounds have been identified as potential CASP14 inducers:

• Oleuropein: A polyphenol from olive oil that upregulates CASP14 expression in TNBC cells, leading to cell cycle arrest and apoptosis [28].
• Gallic acid: A plant-derived phenolic acid that increases CASP14 expression in skin squamous cell carcinoma cells, inhibiting proliferation [13].
• Mentha piperita extract: A botanical extract that enhances CASP14 expression and promotes keratinocyte differentiation in vitro [34].
• Tremella polysaccharide: A fungal polysaccharide with moisturizing properties that upregulates CASP14 and other barrier-related genes [68].

6.2 Small-Molecule Inhibitors

Conversely, in cancers where CASP14 exerts oncogenic effects (e.g., gastric cancer), small-molecule inhibitors of CASP14 could be therapeutically beneficial. However, no selective CASP14 inhibitors have been developed to date. The high degree of structural homology between caspases makes the design of isoform-selective inhibitors challenging. Nevertheless, the unique substrate specificity of CASP14, particularly its preference for hydrophobic residues at the P2 position, offers a potential avenue for the development of selective peptidomimetic inhibitors. Virtual screening campaigns targeting the CASP14 active site have identified several lead compounds, including thiazolidinedione derivatives, which are currently in preclinical development [63].

6.3 Pharmacogenomic Implications

Genetic variation in CASP14 may influence the response to drugs used in the treatment of skin disorders. For example, patients carrying the p.Arg140Trp risk allele, which reduces CASP14 activity, may respond poorly to topical emollients that rely on NMF production for their efficacy. Conversely, these patients may benefit from treatment with retinoids, which upregulate CASP14 expression via the vitamin D receptor (VDR) and retinoic acid receptor (RAR) pathways [66]. Pharmacogenomic testing for CASP14 variants could therefore guide personalized treatment decisions in dermatology.

7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of bioinformatic resources and database accessions for CASP14:

Related Clinical & Scientific Guides

• PMCH Gene: Structure, Function, and Clinical Significance
• CYLC1 Gene: Structure, Function, and Clinical Significance
• CRX Gene: Structure, Function, and Clinical Significance

References

1. Lu, X., Zhang, G., Yang, H., Shan, M., Zhang, X., Wang, Y., Bai, J., & Pan, Z. (2024). Tissue-specific and functional loci analysis of CASP14 gene in the sheep horn. bioRxiv. https://www.semanticscholar.org/paper/0f72b4e4f8412932d99f873a43a3af64b2e0819f
2. Won, H. S., Kim, Y.-S., Seo, K.-J., Jun, S.-Y., Sun, D., Choi, M., Yoon, J.-S., & Byun, J. (2025). Spatial gene expression profiling identifies prognostic features of residual tumors after neoadjuvant chemotherapy in triple-negative breast cancer. Frontiers in Oncology. https://www.semanticscholar.org/paper/89f8cedddf849cb364cd8170f026e02bfc889e8e
3. Madrigal, A., Kim, M., Mehrjoo, Z., Nishimura, T., Saatci, O., Osakwe, A., Zavacky, E., Moslemi, E., Glennon, K., Dankner, M., Maritan, S., Kuasne, H., Pilon, V., Monast, A., Soytas, M., Arseneault, M., Oikonomopoulos, S., Harutyunyan, A., Lu, T., Rayes, R., Soto, L. M., Hernandez-Corchado, A., Spicer, J., Petrecca, K., Siegel, P., Park, M., Ragoussis, J., Şahin, O., Brimo, F., Tanguay, S., Riazalhosseini, Y., & Najafabadi, H. (2026). Single-cell gene programs define subtype identity and metastatic trajectories in renal cell carcinoma. medRxiv. https://www.semanticscholar.org/paper/e4fe3906fc496de7fb832603d8ccc5297a25513e
4. Ratovitski, E. (2013). Phospho‐ΔNp63α regulates AQP3, ALOX12B, CASP14 and CLDN1 expression through transcription and microRNA modulation. FEBS Letters. https://www.semanticscholar.org/paper/32c05285f2194b547055b79f13cf701734869a19
5. Jeon, S., Han, S., Lee, K.-M., Choi, J., Park, S. K., Park, A., Ahn, H., Shin, H. Y., K, H. J., Koo, H., Seo, J., Choi, J. E., Kim, H., Ahn, Y., Kang, D. (2013). Genetic variants of AICDA/CASP14 associated with childhood brain tumor. Genetics and Molecular Research. https://www.semanticscholar.org/paper/6f9cc2ebc65728dc91daf2fc8564f3c0945dda49
6. Gürel, G., Elmas, M., & Göğüş, B. (2022). A case of autosomal recessive congenital ichthyosis with a novel mutation identified in the TGM1 gene by whole exome sequencing. Journal of Biochemical and Clinical Genetics. https://www.semanticscholar.org/paper/102bf9439d4fe59d0aec5f5328cb24f6bbf03fb3
7. Wu, Y., Ni, J., Qi, M., Cao, C., Shao, Y., Xu, L., Ma, H., & Yang, L. (2017). Associations of genetic variation in CASP3 gene with noise-induced hearing loss in a Chinese population: a case–control study. Environmental Health. https://www.semanticscholar.org/paper/f9f69cc50f11a98a5c601b39d228e921d923d7d3
8. Alesi, V., Dentici, M. L., Loddo, S., Genovese, S., Orlando, V., Calacci, C., Pompili, D., Dallapiccola, B., Digilio, M. C., & Novelli, A. (2018). Confirmation of BRD4 haploinsufficiency role in Cornelia de Lange–like phenotype and delineation of a 19p13.12p13.11 gene contiguous syndrome. Annals of Human Genetics. https://www.semanticscholar.org/paper/f23df1b8aef83253d6ee747e95acc9436c678da0
9. Zhang, X., Zhang, Y., Zhao, L., Zhao, Y., Qian, W., Gai, G., Song, J., Du, P., Han, H., & Zhang, Z. (2026). Identification of key candidate genes for body weight traits in male Dongfeng sika deer based on genome-wide association analysis. Scientific Reports. https://www.semanticscholar.org/paper/f23c751a20ec1ef013819d4cf01a5896893ba112
10. Thyssen, J. P., Laursen, A. M., Husemoen, L. L. N., Stender, S., Szecsi, P. B., Menné, T., Johansen, J. D., & Linneberg, A. (2016). Variants in caspase‐14 gene as risk factors for xerosis and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. https://www.semanticscholar.org/paper/e7572f5513349cd3985ea2908ab6197472d4ad72
11. Pattnaik, A., & Naik, P. K. (2024). Identification of differential expressed genes and its related pathways in Hela cell line treated with urea noscapine as potent anticancer agent. Journal of Applied Biology & Biotechnology. https://www.semanticscholar.org/paper/70b5c1442cfe340634f6067e070fb29930ef75ee
12. Schulten, H.-J., Bangash, M., Karim, S., Dallol, A., Hussein, D., Merdad, A., Al-thoubaity, F., Al-Maghrabi, J., Jamal, A., Al-Ghamdi, F., Choudhry, H., Baeesa, S. S., Chaudhary, A., & Alqahtani, M. H. (2017). Comprehensive molecular biomarker identification in breast cancer brain metastases. Journal of Translational Medicine. https://www.semanticscholar.org/paper/990f9b5a45fba392e441492644f64c7ae7bcf72f
13. de Jesus, S. F., de Souza, M. G., Queiroz, L. d. R. P., de Paula, D. P. S., Tabosa, A. T. L., Alves, W. S. M., da Silveira, L. H., Ferreira, A. T. d. S., Martuscelli, O. J. D., Farias, L. C., de Paula, A. M. B., Santos, S. H. S., & Guimarães, A. L. S. (2022). Gallic Acid has an inhibitory effect on skin squamous cell carcinoma and acts on the heat shock protein HSP90AB1. Gene. https://www.semanticscholar.org/paper/d732919da89fe9b29901742ba981c1ef59a38060
14. Hu, K., Yao, L., Zhou, L., & Li, J. (2022). Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma. International Journal of General Medicine. https://www.semanticscholar.org/paper/d6e3f6ebba652f1790a95891a5bbf2e6e9091b39
15. Ding, W., Fan, L., Tian, Y., & He, C. (2021). Study of the protective effects of cosmetic ingredients on the skin barrier, based on the expression of barrier-related genes and cytokines. Molecular Biology Reports. https://www.semanticscholar.org/paper/d0c43824f8d3ab06842e7cbea964ab53e503ef7a
16. Nopriyati, Deddy, D., Rusmawardiana, & Devi, M. (2021). Epidermal Proliferation and Differentiation in Ichthyosis Vulgaris. Scientific Publication. https://www.semanticscholar.org/paper/92b01bbfe67b9fd6e9ff99665d37c49283371bc1
17. Margolis, S., Hammond, K., & Qureshi, M. (2005). Apoptotic gene expression in Alzheimer disease: a preliminary report. Scientific Publication. https://www.semanticscholar.org/paper/9125b01c90510e313ce30241441f10a3d3777e03
18. Yang, X., Pfeiffer, R. M., Wheeler, W., Yeager, M., Chanock, S., Tucker, M. A., & Goldstein, A. M. (2009). Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. International Journal of Cancer. https://www.semanticscholar.org/paper/3d61275d0f0931abd568292d3f593d0a82332d3d
19. Akbar, A., Bint-E-Farrakh, M., Crosby, A. H., Gul, A., & Harlalka, G. V. (2019). Variants in NIPAL4 and ALOXE3 cause autosomal recessive congenital ichthyosis in Pakistani families. Congenital Anomalies. https://www.semanticscholar.org/paper/294195ccc9e7a38ff523d25bff266ddf7d6e0f5e
20. Sun, Q., Chen, Y., Yuan, S., & Liao, J. (2018). Exploration of immunogene in colon cancer recurrence. Scientific Publication. https://www.semanticscholar.org/paper/43b5c643e50e4fb1c24dbc50f4be0988ed2f8098
21. Jelsig, A. M., Brasch-Andersen, C., Kibæk, M., & Fagerberg, C. (2012). A case of microdeletion of 19p13 with intellectual disability, hypertrichosis, synophrys, and protruding front teeth. European Journal of Medical Genetics. https://www.semanticscholar.org/paper/3dbac2bec1ddb4c5dce8d1ab867117c872fd0f3d
22. Huang, Y. J., Zhang, N., Bersch, B., Fidelis, K., Inouye, M., Ishida, Y., Kryshtafovych, A., Kobayashi, N., Kuroda, Y., Liu, G., LiWang, A., Gurla, S. V. T., Wu, N., Yamazaki, T., & Montelione, G. T. (2021). Assessment of Prediction Methods for Protein Structures Determined by NMR in CASP14: Impact of AlphaFold2. Proteins: Structure, Function, and Bioinformatics. https://www.semanticscholar.org/paper/40bccf626eef9c384b4453c6fb02135dd91f2a2e
23. Kirchmeier, P., Zimmer, A., Bouadjar, B., Rösler, B., & Fischer, J. (2017). Whole-Ex